Related Experiment Video
Updated: Oct 22, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.4K
Extreme Hypofractionation with SBRT in Localized Prostate Cancer
Maria Antonia Gómez-Aparicio1, Jeannette Valero2, Begoña Caballero3
1Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain.
Current Oncology (Toronto, Ont.)
|August 26, 2021
Summary
Stereotactic body radiation therapy (SBRT) offers precise, shortened treatment for prostate cancer. This review examines SBRT
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Background:
- Prostate cancer is a leading global cancer diagnosis in men.
- Radiotherapy is a primary treatment for localized prostate cancer.
- Advancements in radiation delivery enhance precision and shorten treatment time.
Purpose of the Study:
- To review the efficacy and toxicity of Stereotactic Body Radiation Therapy (SBRT) for non-metastatic prostate cancer.
- To discuss the feasibility of integrating SBRT into standard clinical practice.
Main Methods:
- Literature review of efficacy and toxicity data for SBRT in prostate cancer.
- Analysis of radiobiological principles guiding hypofractionation.
Main Results:
- SBRT involves delivering radiation in 1-5 fractions.
- Data on SBRT's effectiveness and side effects in non-metastatic prostate cancer were assessed.
- Potential for clinical implementation was evaluated.
Conclusions:
- SBRT is an extreme form of hypofractionated radiotherapy.
- The review provides insights into SBRT's role in managing localized prostate cancer.
- Further discussion on routine clinical adoption is warranted.
